TELA Bio, Inc. (TELA) Tops Q4 EPS by 1c, Offers Guidance

TELA Bio, Inc. (NASDAQ: TELA) reported Q4 EPS of ($0.52), $0.01 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.18 million.

GUIDANCE:

TELA Bio, Inc. sees Q1 2023 revenue of $60-65 million, versus the consensus of $59.6 million.

For earnings history and earnings-related data on TELA Bio, Inc. (TELA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• John Wiley & Sons, Inc. (WLY) Tops Q4 EPS by 12c; offers outlook